Flame Biosciences, Inc.
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Latest on Flame Biosciences, Inc.
The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col
Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected
The search for promising new targets in cancer immunotherapy is one of the top priorities in biopharma and Claudin18.2’s potential in gastric cancer has become one of the hottest emerging areas. That
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sol-Gel Hopes To Bring PellePharm’s Pat